NLS Pharmaceutics Ltd. — Investor Relations & Filings
Filings indexed
360
across all filing types
Latest filing
2026-04-30
Regulatory Filings
Country
US
United States of America
Listing
US
NLSP
NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of therapies for patients with rare and complex central nervous system (CNS) disorders. The company's primary focus areas include sleep disorders, neurodegenerative diseases, and attention-deficit/hyperactivity disorder (ADHD). Its lead product candidates are Quilience, a proprietary extended-release formulation of mazindol for the treatment of narcolepsy, and Nolazol for ADHD. NLS Pharmaceutics is also advancing its pipeline with additional assets, such as the AEX-6xx series, to address other CNS-related conditions.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 6-K - NewcelX Ltd. (0001783036) (Filer) | 2026-04-30 | English | |
| 6-K - NewcelX Ltd. (0001783036) (Filer) | 2026-04-20 | English | |
| 6-K - NewcelX Ltd. (0001783036) (Filer) | 2026-04-01 | English | |
| 6-K Filing | 2026-02-12 | English | |
| 6-K Filing | 2026-01-29 | English | |
| REPORT OF FOREIGN PRIVATE ISSUER | 2026-01-12 | English |
Browse filings by year
8 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
7 filings
| |||||
| 39082389 | 6-K - NewcelX Ltd. (0001783036) (Filer) | 2026-04-30 | English | ||
| 34690932 | 6-K - NewcelX Ltd. (0001783036) (Filer) | 2026-04-20 | English | ||
| 33150227 | 6-K - NewcelX Ltd. (0001783036) (Filer) | 2026-04-01 | English | ||
| 31695679 | 6-K Filing | 2026-02-12 | English | ||
| 31695816 | 6-K Filing | 2026-01-29 | English | ||
| 13193183 | REPORT OF FOREIGN PRIVATE ISSUER | 2026-01-12 | English | ||
| 13193185 | REPORT OF FOREIGN PRIVATE ISSUER | 2026-01-05 | English | ||
|
2025
8 filings
| |||||
| 13193187 | REPORT OF FOREIGN PRIVATE ISSUER | 2025-12-11 | English | ||
| 13193186 | REPORT OF FOREIGN PRIVATE ISSUER | 2025-11-20 | English | ||
| 13193188 | Regulatory Filings 2025 | 2025-11-19 | English | ||
| 13193189 | Regulatory Filings 2025 | 2025-11-19 | English | ||
| 13193190 | REPORT OF FOREIGN PRIVATE ISSUER | 2025-11-17 | English | ||
| 13193191 | Major Shareholding Notification 2025 | 2025-11-14 | English | ||
| 13193192 | Major Shareholding Notification 2025 | 2025-11-13 | English | ||
| 13193193 | Major Shareholding Notification 2025 | 2025-11-13 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Alpha Tau Medical Ltd.
Clinical-stage oncology firm developing alpha radiation the…
|
DRTS | US | Professional, scientific and te… |
|
Alteogen Inc.
Biopharmaceutical firm developing biologics with proprietar…
|
196170 | KR | Professional, scientific and te… |
|
ALTERITY THERAPEUTICS LIMITED
Clinical-stage developer of disease-modifying therapies for…
|
ATH | AU | Professional, scientific and te… |
|
AlzeCure Pharma
Develops therapies for severe diseases, focusing on Alzheim…
|
ALZCUR | SE | Professional, scientific and te… |
|
AMPLIA THERAPEUTICS LIMITED
Clinical-stage developer of FAK inhibitors for solid tumors…
|
ATX | AU | Professional, scientific and te… |
|
ANAPTYSBIO, INC
Clinical-stage biotech developing immunology therapeutics f…
|
ANAB | US | Professional, scientific and te… |
|
ANATARA LIFESCIENCES LTD
Develops non-antibiotic gastrointestinal health solutions f…
|
ANR | AU | Professional, scientific and te… |
|
AngioLab, Inc.
Develops angiogenesis inhibitors for pharmaceuticals and he…
|
251280 | KR | Professional, scientific and te… |
|
Anhui Wanbang Pharmaceutical Technology Co.,Ltd.
Pharmaceutical CRO specializing in clinical trials, BE stud…
|
301520 | CN | Professional, scientific and te… |
|
Anixa Biosciences Inc
A clinical-stage biotech developing therapies and vaccines …
|
ANIX | US | Professional, scientific and te… |
NLS Pharmaceutics Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35193/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35193 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35193 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35193 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35193}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for NLS Pharmaceutics Ltd. (id: 35193)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.